Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab

BACKGROUND: Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Graham, Maya S, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie M, Zhang, Zhigang, Dunphy, Mark P, Kaley, Thomas, Young, Robert J
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7236386/
https://ncbi.nlm.nih.gov/pubmed/32642703
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa050
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados